[go: up one dir, main page]

ES2052478T1 - RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS. - Google Patents

RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS.

Info

Publication number
ES2052478T1
ES2052478T1 ES91900526T ES91900526T ES2052478T1 ES 2052478 T1 ES2052478 T1 ES 2052478T1 ES 91900526 T ES91900526 T ES 91900526T ES 91900526 T ES91900526 T ES 91900526T ES 2052478 T1 ES2052478 T1 ES 2052478T1
Authority
ES
Spain
Prior art keywords
hiv
particles
recombinants
reproduction
possibility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES91900526T
Other languages
Spanish (es)
Inventor
Omar K Haffar
Shiu-Lok Hu
Allen W Senear
Bruce M Travis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of ES2052478T1 publication Critical patent/ES2052478T1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN PARTICULAS RETROVIRALES CONVERTIDAS EN RECOMBINANTES SIN POSIBILIDAD DE REPRODUCCION QUE TIENEN CARACTERISTICAS ESTRUCTURALES, MORFOLOGICAS E INMUNOLOGICAS MUY SIMILARES A LAS DE LOS RETROVIRUS HUMANOS NATIVOS. EL METODO DE LA INVENCION CONSISTE EN LA COEXPRESION DE UN NUCLEO RETROVIRAL MADURO Y DE PROTEINAS ESTRUCTURALES ENVOLVENTES EN CELULAS HUESPEDES DE MAMIFEROS DE MODO QUE LAS PROTEINAS RETROVIRALES EXPRESADAS SE ASOCIAN EN PARTICULAS RETROVIRALES DE BROTE UNIDAS. EN UNA PUESTA EN PRACTICA PARTICULAR DE LA INVENCION, LAS PARTICULAS DE VIH-1 CONVERTIDAS EN RECOMBINANTES SIN POSIBILIDAD DE REPRODUCCION SE PRODUCEN A BASE DE COINFECTAR CELULAS HUESPEDES DE MAMIFEROS CON UN VIRUS DE VACUNA RECOMBINANTE QUE LLEVA LA PORCION DEL VIRUS DE INMUNODEFICIENCIA HUMANA TIPO Q (VIH-1) Y GENES DE PROTEASA Y UN VIRUS DE VACUNA RECOMBINANTE QUE LLEVA EL GEN ENVOLVENTE DEL VIH-1. ESTAS PARTICULAS DE VIH-1 CONVERTIDAS EN RECOMBINANTES SIN POSIBILIDAD DE REPRODUCCION TIENEN UNAS CARACTERISTICAS INMUNOLOGICAS Y MORFOLOGICAS MUY PARECIDAS A LAS DEL VIH-1 NATIVO, SON CAPACES DE BLOQUEAR LA INFECTIVIDAD DEL VIH VIVO IN VITRO Y SON MUY INMUNOGENICAS IN VIVO. LAS PARTICULAS DE VIH-1 CONVERTIDAS EN RECOMBINANTES SIN POSIBILIDAD DE REPRODUCCION DE LA INVENCION SE PUEDEN UTILIZAR COMO AGENTES ANTIVIRALES Y COMO INMUNOGENES EN FORMULAS PARA VACUNAS EFECTIVAS PARA INHIBIR O PREVENIR LA INFECCION POR VIH Y/O EL DESARROLLO DEL SINDROME DE INMUNODEFICIENCIA ADQUIRIDA.RETROVIRAL PARTICLES CONVERTED IN RECOMBINANTS WITH NO POSSIBILITY OF REPRODUCTION ARE DESCRIBED, HAVING STRUCTURAL, MORPHOLOGICAL AND IMMUNOLOGICAL CHARACTERISTICS VERY SIMILAR TO THOSE OF NATIVE HUMAN RETROVIRUSES. THE METHOD OF THE INVENTION CONSISTS OF THE COEXPRESSION OF A MATURE RETROVIRAL NUCLEUS AND OF ENVELOPE STRUCTURAL PROTEINS IN MAMMAL HOSPITAL CELLS SO THAT THE EXPRESSED RETROVIRAL PROTEINS ARE ASSOCIATED IN RETROID PARTICLES. IN A PARTICULAR PRACTICE OF THE INVENTION, THE HIV-1 PARTICLES CONVERTED IN RECOMBINANTS WITH NO POSSIBILITY OF REPRODUCTION ARE PRODUCED BASED ON COINFECTING CELLS HOSPED BY MAMMALS WITH A RECOMBINANT VACCINE VACCINE VIRUSED BY THE VODUNCIATION OF VIVUNIUM (HIV-1) AND PROTEASE GENES AND A RECOMBINANT VACCINE VIRUS CARRYING THE ENVELOPING GENE OF HIV-1. THESE PARTICLES OF HIV-1 BECOMING RECOMBINANTS WITH NO POSSIBILITY OF REPRODUCTION HAVE VERY IMMUNOLOGICAL AND MORPHOLOGICAL CHARACTERISTICS OF NATIVE HIV-1, ARE CAPABLE OF BLOCKING THE INFECTIVITY OF LIVING HIV IN VITRO AND ARE VERY INOUGH. PARTICLES OF HIV-1 BECOMING RECOMBINANTS WITH NO POSSIBILITY OF REPRODUCTION OF THE INVENTION MAY BE USED AS ANTIVIRAL AGENTS AND AS IMMUNOGENES IN EFFECTIVE VACCINES FOR INHIBITING OR PREVENTING DEVELOPMENT OF HIV INFECTION AND / OR DEVELOPMENT.

ES91900526T 1989-11-20 1990-11-20 RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS. Pending ES2052478T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43920589A 1989-11-20 1989-11-20

Publications (1)

Publication Number Publication Date
ES2052478T1 true ES2052478T1 (en) 1994-07-16

Family

ID=23743729

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900526T Pending ES2052478T1 (en) 1989-11-20 1990-11-20 RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS.

Country Status (14)

Country Link
EP (1) EP0502105A4 (en)
JP (1) JPH05503629A (en)
KR (1) KR920703639A (en)
AU (1) AU636944B2 (en)
CA (1) CA2068713A1 (en)
ES (1) ES2052478T1 (en)
FI (1) FI922277A7 (en)
GR (1) GR930300005T1 (en)
HU (1) HUT60506A (en)
NO (1) NO921969L (en)
OA (1) OA09698A (en)
TW (1) TW216446B (en)
WO (1) WO1991007425A1 (en)
ZA (1) ZA909302B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015141A2 (en) * 1989-06-01 1990-12-13 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
DE4124817A1 (en) * 1991-07-26 1993-01-28 Basf Ag AQUEOUS POLYMER DISPERSIONS
CA2120137C (en) * 1991-11-08 2004-05-04 The Upjohn Company Feline leukemia virus vaccines
AU2462392A (en) * 1992-04-14 1993-11-18 British Biotech Pharmaceuticals Limited Induction of CTL responses
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
EP1770168A3 (en) * 1993-01-26 2009-05-06 The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) Compositions and methods for delivery of genetic material
PT681483E (en) 1993-01-26 2005-11-30 Wyeth Corp COMPOSITIONS AND METHODS FOR DISTRIBUTION OF GENETIC MATERIAL
GB9304239D0 (en) * 1993-03-01 1993-04-21 British Bio Technology Viral particles
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US5858838A (en) 1998-02-23 1999-01-12 Taiwan Semiconductor Manufacturing Company, Ltd. Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
EP0817854A2 (en) * 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Antigen presentation system based on retrovirus-like particles
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
PT1141315E (en) 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Modified hiv env polypeptides
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
CN1311871C (en) 2000-03-02 2007-04-25 爱莫里大学 DNA expression vector and its application method
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
AU2002252199B2 (en) * 2001-03-08 2008-01-03 Emory University MVA expressing modified HIV envelope, GAG, and POL genes
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
ES2606511T3 (en) 2011-04-06 2017-03-24 Biovaxim Limited Pharmaceutical compositions to prevent and / or treat an HIV disease in humans
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA55321A (en) * 2019-03-15 2022-01-19 Modernatx Inc RNA VACCINES AGAINST HIV

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752565A (en) * 1986-04-07 1988-06-21 The United States Of America As Represented By The Department Of Health And Human Services Cell line producing AIDS viral antigens without producing infectious virus particles
JPH02203783A (en) * 1989-02-02 1990-08-13 Banyu Pharmaceut Co Ltd Cloned human t cell forming non-virulent aids virus having antigenicity
JP3140757B2 (en) * 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート Packaging defective HIV provirus, cell lines and uses thereof
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
JPH05501201A (en) * 1989-10-16 1993-03-11 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ Non-infectious HIV-1 particles and their uses

Also Published As

Publication number Publication date
FI922277A0 (en) 1992-05-19
EP0502105A1 (en) 1992-09-09
HU9201659D0 (en) 1992-08-28
CA2068713A1 (en) 1991-05-21
TW216446B (en) 1993-11-21
ZA909302B (en) 1991-09-25
OA09698A (en) 1993-08-30
EP0502105A4 (en) 1993-02-24
AU6905591A (en) 1991-06-13
NO921969D0 (en) 1992-05-19
JPH05503629A (en) 1993-06-17
WO1991007425A1 (en) 1991-05-30
GR930300005T1 (en) 1993-04-28
FI922277A7 (en) 1992-05-19
NO921969L (en) 1992-06-26
KR920703639A (en) 1992-12-18
AU636944B2 (en) 1993-05-13
HUT60506A (en) 1992-09-28

Similar Documents

Publication Publication Date Title
ES2052478T1 (en) RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS.
ES2061500T5 (en) DIAGNOSIS AND VACCINES OF DELTA HEPATITIS, ITS PREPARATION AND USE.
Karacostas et al. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.
ATE187983T1 (en) RECOMBINANT RETROVIRUSES
ES2150897T3 (en) RECOMBINANT MANUFACTURING PROCEDURE OF PROTEINS DERIVED FROM HIV-2 AND CELL CULTURE THAT EXPRESSES HIV-2 PROTEINS.
DK513388D0 (en) PEPTIDES WITH IMMUNOLOGICAL PROPERTIES RESPONSIBLE FOR HIV-2 VIRUSES, NUCLEOTIDE SEQUENCES CODING FOR SUCH PEPTIDES, ANTIGEN AND IMMUNOGENIC AGENTS CONTAINING SUCH PEPTIDES AND PROCEDURES AND HIV KIT TILT INIT
WO1991002805A3 (en) Recombinant retroviruses delivering vector constructs to target cells
ES2166749T3 (en) NANBV DIAGNOSTICS: USEFUL POLINUCLEOTIDES TO DISCRIMINATE HEPATITIS VIRUSES.
ES2052368T3 (en) BLOOD FACTORS PRODUCED BY RECOMBINATION AND THE PROCESS FOR THE EXPRESSION OF SUCH FACTORS, AS WELL AS RECOMBINATION OF THE VACCINE VIRUSES USED IN SUCH PROCESS.
DE3850683D1 (en) Hybrid RNA virus.
ES2070997T3 (en) RECOMBINANT HERPES VIRUSES OF TURKEYS AND LIVING VECTOR VACCINES DERIVED FROM THEM.
CY1106513T1 (en) TRIPLE LENTINOIC DNA AND VEHICLES AND RECOMBINANT CELLS CONTAINING TRIPLE LENTINOIC DNA
CU20000126A7 (en) HIV-1 TAT DERIVATIVES OF THE SAME FOR PROPHYACTIC AND THERAPEUTIC VACCINATION
AR003425A1 (en) RECOMBINANT MAPACHE POXVIRUS, VACCINE FOR USE IN CATS AND USE OF POXVIRUS TO PREPARE A VACCINE USEFUL TO AVOID OR DECREASE THE DISEASE CAUSED BY THE FELINE IMMUNODEFICIENCY VIRUS (IVF)
ES2134197T3 (en) VACCINES AGAINST HERPES SIMPLEX VP16 VIRUSES.
ES2056565T3 (en) RECOMBINANT VIRUSES OF MAREK'S DISEASE.
ES2115622T3 (en) MOLECULAR CLONES OF HIV-1 AND USES THEREOF.
ES2061603T3 (en) VIRAL MUTANTS OF INFECTIOUS BOVINE RHINOTRACHEITIS, VACCINES THAT CONTAIN THEM, METHODS FOR THE PRODUCTION OF THE SAME AND METHODS FOR THE USE OF THE SAME.
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.
ES2195994T3 (en) RECEIVING VIRUS OF MAREK'S DISEASE, THIS PREPARATION PROCEDURE; AND VACCINE THAT CONTAINS IT.
ES2062990T3 (en) VACCINES, WHICH CONTAIN PROTEIN F FROM AIDS VIRUSES.
DK631387A (en) viral vector
WO2022035860A3 (en) Replication-competent adenovirus type 4-hiv env vaccines and their use
WO2022147891A1 (en) Cochlear outer hair cell regenerated by ectopic joint overexpression of atoh1 and ikzf2 and application thereof
DK284389D0 (en) PRECURSOR ANTIGENES